**Diffuse Large B-Cell Lymphoma (BCEL)**

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **BCEL-C 2 of 4 and HGBL-1** | Internal request  
In response to the FDA approval of bendamustine, rituximab and polatuzumab vedotin-piiq for the treatment of relapsed or refractory DLBCL, the panel voted on the addition of this regimen.  
  
External request  
Submission request from Genentech to consider inclusion of polatuzumab vedotin in combination with BR as a treatment option for “Second-line and Subsequent Therapy” in patients with relapsed or refractory DLBCL (BCEL-C 2 of 4).  
  
**BCEL-C 2 of 4** | Based upon the FDA approval and the noted reference, the panel consensus was to include bendamustine, rituximab and polatuzumab vedotin-piiq as an option with category 2A recommendation for the following indications:  
- Relapsed/refractory DLBCL in non-candidates for transplant (after ≥ 2 prior therapies)  
- Relapsed/refractory high-grade B-cell lymphomas with translocations of MYC and BCL2 and/or BCL6 (Double/Triple Hit Lymphoma) in non-candidates for transplant (after ≥ 2 prior therapies)  
  
Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study [abstract]. Blood 2018;132: Abstract 1683.                                                                                          | YES 19 NO 0 ABSTAIN 1 ABSENT 8 |
| Internal request  
Comment to reassess the inclusion of bendamustine ± rituximab as a relapsed/refractory DLBCL in non-candidates for transplant. | Based on the data in the noted reference, the panel consensus was for bendamustine ± rituximab to remain an option with a category designation change from a category 2A to category 2B.  
  
Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study [abstract]. Blood 2018;132: Abstract 1683.                                                                                          | YES 11 NO 8 ABSTAIN 1 ABSENT 8 |